ReviewThe Journal of clinical and aesthetic dermatology2019
Intravenous Hyaluronidase for Visual Loss Secondary to Filler Injection: A Novel Therapeutic Approach.
Review in The Journal of clinical and aesthetic dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Hyaluronidase Protocol in Management of Hyaluronic Acid Filler-Related Vascular Complications: A Systematic Review and Meta-Analysis.Aesthetic plastic surgery · 2026Pooled it
- Agarose Gel as an Injectable Filler Significantly Reduced the Risk of Rabbit Retinal Artery Embolism Compared to Hyaluronic Acid.Aesthetic plastic surgery · 2026Article
- Bridging a Century-Old Problem: The Pathophysiology and Molecular Mechanisms of HA Filler-Induced Vascular Occlusion (FIVO)-Implications for Therapeutic Interventions.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the establishment of international expert consensus groups, peer-reviewed guidelines, and evidence-based protocols for both reducing the risk of arterial embolization of hyaluronic acid filler from aesthetic injection and promptly treating complications, perhaps the most devastating complication of visual loss remains largely irreversible. This article examines the novel therapeutic approach of using high-dose intravenous hyaluronidase when other attempts to restore vision have failed. Evidence for the safety of the proposed dosing in an emergency setting has been demonstrated in previous papers investigating the use of hyaluronidase for myocardial infarction in the 1970s. This approach has the advantage of reducing the time delay and risks associated with retrobulbar injection. Though rare, the risk of anaphylaxis must be able to be managed.
Indexed as
Identifiers
32038761PMC7002050W3006733638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.